DE vs DHR: Which Is the Better Buy?
Side-by-side comparison of Deere & Company and Danaher Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Deere & Company · Industrials
$589.24
-29.6% upside to fair value
Grade D
High Quality
VS
Danaher Corporation · Healthcare
$177.17
+8.9% upside to fair value
Grade B
High Quality
QuantHub Verdict
DHR has more upside to fair value
(+8.9%).
DE trades at a lower forward P/E
(33.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DE |
DHR |
| Current Price |
$589.24 |
$177.17 |
| Fair Value Estimate |
$414.61 |
$192.90 |
| Upside to Fair Value |
-29.6%
|
+8.9%
|
| Market Cap |
$159.1B |
$125.4B |
| Forward P/E |
33.3x
|
34.1x
|
| EV / EBITDA |
18.8x
|
20.8x
|
| Price / Sales |
3.4x
|
5.1x
|
| Price / FCF |
42.2x
|
23.7x
|
| Revenue Growth YoY |
+6.7%
|
+3.7%
|
| Gross Margin |
35.4%
|
60.7%
|
| Operating Margin |
18.4%
|
21.0%
|
| Return on Equity |
18.3%
|
7.1%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.37%
|
4.22%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Deere & Company is a leading global manufacturer of agricultural, construction, and forestry machinery with a durable competitive moat anchored by its number one market share in large agricultural equipment and a dense dealer network. The company benefits from embedded precision agriculture technology that widens its competitive gap, particularly in North America where it holds 40 to 60 percent m…
Danaher Corporation operates in the healthcare sector, specializing in medical diagnostics and research tools through three balanced platforms: Biotechnology, Life Sciences, and Diagnostics. The company benefits from a durable competitive moat supported by the Danaher Business System, disciplined capital allocation, and a platform-centric organizational structure. Despite modest revenue growth of…
Accumulation Zones
| Metric |
DE |
DHR |
| Zone Low |
$310.96 |
$144.68 |
| Zone High |
$352.42 |
$163.97 |
| In Buy Zone? |
No
|
No
|